GSK 2269557

Drug Profile

GSK 2269557

Alternative Names: GSK 2269557 ELLIPTA DPI; GSK2269557

Latest Information Update: 24 Jan 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antiasthmatics
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma; Chronic obstructive pulmonary disease; Immunodeficiency disorders

Most Recent Events

  • 01 Dec 2016 GlaxoSmithKline completes a phase I trial in Chronic obstructive pulmonary disease (In volunteers) in Japan (NCT02972905)
  • 14 Oct 2016 Phase-I clinical trials in Chronic obstructive pulmonary disease (In healthy volunteers) in Japan (Inhalation) (NCT02972905)
  • 01 Sep 2016 GlaxoSmithKline completes a phase II trial in Asthma in Germany (NCT02567708)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top